Cannabis genetics, breeding & chemovars — the knowledge hub
Before a strain carries a name, there is genetics: alleles at a handful of key loci that determine whether a plant produces mostly THC, CBD, or both, and a complex interplay of many genes that shapes terpene profile and growth habit. The colloquial 'Indica' and 'Sativa' labels describe, at best, growth morphology — not effect or ancestry. This hub explains the genetics behind the site's 91 strain profiles: the chemotype model, landrace origins, hybridisation, terpene inheritance, and autoflowering genetics — each referenced to the underlying scientific literature.
The chemovar model: chemical profiles instead of botanical myths
The traditional classification into Indica and Sativa falls short scientifically, as it only describes external characteristics such as leaf shape and growth height. In modern pharmacology and breeding, the chemovar model has therefore become established. This classifies cannabis plants into different main types based on their actual chemical constituents. Type I chemovars have a high THC content, Type II chemovars show a balanced ratio of THC to CBD, while Type III chemovars are dominated by a high proportion of CBD. This precise classification enables reliable therapeutic application and standardised breeding results.
In addition to the main cannabinoids, terpenes play a decisive role in defining a chemovar. These aromatic compounds, such as myrcene, limonene, or linalool, not only influence the smell but also modulate the effect of cannabinoids on the human endocannabinoid system. In this context, research refers to the synergy effect, in which the entirety of the plant substances unfolds a more specific effect than isolated individual substances. For modern breeding programmes, the targeted control of this terpene profile is therefore just as important as the stabilisation of cannabinoid concentrations.
- Type I chemovars: dominance of tetrahydrocannabinol for specific applications.
- Type II chemovars: Balanced profiles with synergistic action of both main cannabinoids.
- Type III chemovars: CBD-dominant genetics with minimal psychoactive potential.
- Terpene profiles: Essential oils as functional modulators of the overall effect.
Modern breeding methods and genetic stability
The development of stable cannabis strains requires in-depth agricultural knowledge and precise selection processes. Through hybridization, i.e. the targeted crossing of different landraces or established lines, breeders attempt to combine advantageous traits such as pest resistance, yield strength, and specific active ingredient profiles. A major challenge in this process is genetic instability in the first generations. Only through multiple backcrossing and selective inbreeding over several generations can homogeneous strains be produced whose offspring reliably exhibit the desired characteristics without unwanted deviations.
A significant advance in genetics is the integration of genes from the wild Ruderalis plant, which are responsible for the development of autoflowering strains. These plants flower independently of the light cycle after a certain vegetative period. The challenge for breeders is to successfully combine this trait with the high active ingredient concentrations of photoperiod plants. Through modern molecular biological marker analyses, breeders can now identify at an early stage which seedlings carry the desired genetic traits, significantly accelerating the lengthy selection process.
- Hybridization: Crossing of genetically diverse lines to achieve heterosis effects.
- Backcrossing: Stabilization of specific traits over several plant generations.
- Autoflowering genetics: Light-independent flowering phase through the crossbreeding of Cannabis ruderalis.
- Marker-assisted selection: Efficient identification of desired genotypes in the laboratory.
Genetics in Swiss law and practice
In Switzerland, the legal classification of cannabis genetics is directly linked to the content of the psychoactive active substance THC. Plants and products with a total THC content of less than one percent do not fall under the Narcotics Act. This allows for liberal breeding, propagation, and distribution of CBD-rich genetics in the agricultural sector. For medical purposes, on the other hand, where cannabis medicines have been allowed to be prescribed by doctors without a BAG exceptional permit since August 2022, the strictest quality requirements of Swissmedic apply, prescribing a seamless standardization of genetics and active ingredient profiles.
The implementation of state-supervised pilot trials in various Swiss cities also requires highly controlled genetics. The strains used in projects such as Züri Can or Weed Care must be cultivated under strict organic farming guidelines and must not exceed defined THC limits. The import of seeds and cuttings for these scientific projects is subject to close control by the Federal Office of Public Health (FOPH) and the Federal Food Safety and Veterinary Office (FSVO) to guarantee the purity of the genetics and the exclusion of pesticides or heavy metals.
- Limit regulation: Free handling of genetics with less than one percent total THC.
- Medical cannabis: Strict guidelines for standardized active substance profiles according to Swissmedic.
- Pilot trials: Controlled cultivation of certified genetics for scientific studies.
- Official control: Quality assurance by the FOPH, FSVO, and cantonal enforcement authorities.
FAQ
What is the difference between the genotype and the phenotype of a cannabis plant?
The genotype represents the genetic blueprint of a cannabis plant, which is determined by crossing the parent plants. It defines the theoretical potential for growth form, cannabinoid, and terpene production. The phenotype, on the other hand, is the actual, visible, and measurable appearance of the plant. It arises from the interaction of the genotype with external environmental influences such as light spectrum, temperature, nutrients, and irrigation. Under different conditions, visually and chemically varying plants can grow from the same genetics.
What is the legal status of cannabis seeds and cuttings in Switzerland?
In Switzerland, cannabis seeds and cuttings are legally available as long as they are intended for the cultivation of plants with a total THC content of less than one percent. These CBD genetics are not subject to the Narcotics Act. The acquisition and cultivation of genetics with a THC content of over one percent is illegal for private individuals and is punished with fixed penalty fines for small quantities. Exceptions apply to medical cultivation under Swissmedic supervision as well as to the official scientific pilot trials approved by the FOPH.
Why is the classification into Indica and Sativa unreliable for the effect?
The terms Indica and Sativa primarily describe botanical morphology, i.e., growth height, leaf shape, and origin of the plant. However, they do not allow for reliable conclusions regarding the chemical composition and thus the actual effect on the human body. Due to decades of hybridization, pure strains are extremely rare. Instead, the effect is significantly determined by the specific chemovar, i.e., the complex interaction of THC, CBD, other minor cannabinoids, and the individual terpene profile of the respective flower.